头孢他啶联合左氧氟沙星对心力衰竭肺部感染患者炎症因子水平的影响

Effect of Ceftazidime combined levofloxacin on inflammatory factor levels in patients with heart failure and lung infection

目的观察头孢他啶联合左氧氟沙星对心力衰竭合并肺部感染患者炎症因子表达水平的影响。方法收集110例心力衰竭合并肺部感染患者的临床资料,均采用头孢他啶联合左氧氟沙星作为抗炎方案,分别取治疗前、连续治疗3d后、连续治疗1周后外周静脉血,测定血清降钙素原(procalcitonin,PCT)、C反应蛋白(C-reactionprotein,CRP)的表达水平,并行统计学对比。结果 110例患者连续治疗1周后血清PCT(2.4±0.5)ng/ml,CRP(19.4±2.3)mg/L,两项数据均为最低水平,其次为治疗3d,治疗前二者血清表达水平最高,分别为PCT(11.2±1.4)ng/ml、CRP(104.4±9.0)mg/L,不同时间点测定数据比较,差异均存在统计学意义(P<0.05)。结论头孢他啶联合左氧氟沙星治疗心力衰竭合并肺部感染患者,能显著降低患者血清PCT、CRP等炎症因子的表达水平,有效纠正机体感染状态,改善预后,值得临床推广应用。

Objective To observe the effect of Ceflazidime combined levofloxacin inflammation factor expression level in patients with heart failure by pulmonary infection. Methods Collected during 2015.02--2015.02 our hospital diagnosis and treatment of 110 cases of clinical data of pulmonary infection in patients with heart failure, adopt Ceftazidime com- bined levofloxacin as anti - inflammatory, taken before treatment, continuous 3 d after treatment, 1 week after continu- ous peripheral venous blood, serum calcitonin （procalcitonin, PCT） and c- reactive protein （C - reactionprotein, CRP） expression level, comparison of statistics. Results 110 cases of patients with continuous 1 week after treatment serum PCT （2.4 ＋0. 5） ng/ml, CRP （ 19. 4 ＋2. 3） rag/L, two data are the lowest level, followed by 3 d treatment, before treatment both have the highest expression level, serum PCT respectively （ 11.2 ＋ 1.4） ng/ml, CRP （ 104.4 ~ 9.0） mg/L, different time point measurement data comparison, the differences were statistically significant （P 〈 0. 05 ）. Conclusion Ceftazidime with levofloxaein therapy for heart failure patients with pulmonary infection, can sig- nificantly reduce the expression of inflammatory markers in patients with serum PCT and CRP levels, correcting infection status effectively, improve the prognosis, worthy of clinical popularization and application.